{"created":"2020-08-24T05:51:16.074435+00:00","id":3029,"links":{},"metadata":{"_buckets":{"deposit":"0d7f0c87-5e4f-4e35-bd80-1f9d9826bb35"},"_deposit":{"created_by":37,"id":"3029","owner":"37","owners":[37],"owners_ext":{"displayname":"","email":"Papaaung99@gmail.com","username":""},"pid":{"revision_id":0,"type":"recid","value":"3029"},"status":"published"},"_oai":{"id":"oai:meral.edu.mm:recid/3029","sets":["1582963366982","1582963366982:1597649184558"]},"communities":["um1"],"item_1583103067471":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Association between HLA-B* 15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar","subitem_1551255648112":"en"}]},"item_1583103085720":{"attribute_name":"Description","attribute_value_mlt":[{"interim":"Genetic predisposition to carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) had been reported in several Southeast Asian populations, but not in Myanmar. Previous studies had so far reported more than 70% of CBZ-induced SJS/TEN cases\npositive for HLA-B*15:02 allele.1-4 Myanmar, as the second largest country in Southeast Asia with a population of 54.5 million, has high HLA-B*15:02 carrier frequency in its general population (27.3- 49.1%).5,6."}]},"item_1583103108160":{"attribute_name":"Keywords","attribute_value_mlt":[{"interim":"Stevens-Johnson syndrome, Toxic epidermal necrolysis, Carbamazepine, HLA-B*15:02, Myanmar"}]},"item_1583103120197":{"attribute_name":"Files","attribute_type":"file","attribute_value_mlt":[{"date":[{"dateType":"Available","dateValue":"2020-08-24"}],"filename":"Association between HLA-B 15.pdf","filesize":[{"value":"119 Kb"}],"format":"application/pdf","url":{"url":"https://meral.edu.mm/record/3029/files/Association between HLA-B 15.pdf"},"version_id":"d7bed452-b060-46df-8ee0-b9e4b8b75878"}]},"item_1583103131163":{"attribute_name":"Journal articles","attribute_value_mlt":[{"subitem_issue":"3","subitem_journal_title":"Neurology Asia","subitem_pages":"283-285","subitem_volume":"22"}]},"item_1583105942107":{"attribute_name":"Authors","attribute_value_mlt":[{"subitem_authors":[{"subitem_authors_fullname":"Amy Hui-Ping Khor"},{"subitem_authors_fullname":"Seinn Mya Mya Aye"},{"subitem_authors_fullname":"Kheng-Seang Lim"},{"subitem_authors_fullname":"Yan Lynn Aung"},{"subitem_authors_fullname":"Yin Minn Aye"},{"subitem_authors_fullname":"Ohnmar"},{"subitem_authors_fullname":"Win Min Thit"},{"subitem_authors_fullname":"Chong-Tin Tan"},{"subitem_authors_fullname":"Ching-Ching Ng"}]}]},"item_1583108359239":{"attribute_name":"Upload type","attribute_value_mlt":[{"interim":"Publication"}]},"item_1583108428133":{"attribute_name":"Publication type","attribute_value_mlt":[{"interim":"Journal article"}]},"item_1583159729339":{"attribute_name":"Publication date","attribute_value":"2017-12-15"},"item_title":"Association between HLA-B* 15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar","item_type_id":"21","owner":"37","path":["1582963366982","1597649184558"],"publish_date":"2020-08-24","publish_status":"0","recid":"3029","relation_version_is_last":true,"title":["Association between HLA-B* 15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar"],"weko_creator_id":"37","weko_shared_id":-1},"updated":"2021-12-13T07:00:53.872829+00:00"}